In this webinar, we explore market access challenges in Germany, Austria and Switzerland. Clare Foy (Global Market Access Director – Mtech Access) speaks to Dr Stefan Walzer (CEO, President & Founder at MArS Market Access & Pricing Strategy GmbH) about the challenges and opportunities for reimbursement in the German-speaking markets.

Clare and Stefan discuss:
- Preparing for access to Switzerland – a European market outside the EU
- Pricing strategy and HTA decision-making in Austria under the new Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)
- Launching in Germany – is this still one of the most attractive European markets?
- The Financial Stabilisation Act in Germany – what this means for drug pricing

Learn more at: [ Ссылка ]

Jump to:
00:00 - Welcome and introductions
02:25 - Differences in stakeholders and reimbursement processes
04:59 - Market access landscape in Switzerland
15:37 - Market access and pricing in Austria
21:10 - Market access in Germany
31:03 - Changes in Germany since the Financial Stabilisation Act
38:40 - Pricing guardrails and the cap on the revenue for orphan drugs
44:27 - Price negotiations and the price volume agreement
47:58 - Impact on Pharma's global pricing strategy

свернуть